论文部分内容阅读
目的探讨多西他赛联合吉西他滨治疗蒽环类耐药的晚期乳腺癌临床效果。方法收集2011年3月至2012年2月就诊对蒽环类耐药的晚期乳腺癌患者42例,采用多西他赛联合吉西他滨化疗,化疗2个周期后观察治疗结果及不良反应发生情况,2周期治疗后评价近期疗效。结果完全缓解(CR)12例,部分缓解(PR)18例,病情稳定(SD)7例,病情进展(PD)5例,总有效率为71.4%,获益率为88.1%;骨髓抑制、胃肠反应、过敏反应、周围神经毒性、体液潴留及肝肾功能损害均为常见的不良反应,其中骨髓抑制的发生率较高(45.2%)。结论多西他赛与吉西他滨联合化疗对蒽环类耐药的晚期乳腺癌疗效可靠。
Objective To investigate the clinical efficacy of docetaxel plus gemcitabine in the treatment of anthracycline-resistant advanced breast cancer. Methods Forty-two patients with advanced breast cancer who were resistant to anthracycline from March 2011 to February 2012 were selected and treated with docetaxel and gemcitabine. The treatment outcome and adverse reactions were observed after 2 cycles of chemotherapy. 2 Evaluation of the short-term effect after treatment. Results There were 12 cases of complete remission (CR), 18 cases of partial remission (PR), 7 cases of stable disease (SD) and 5 cases of progression (PD). The total effective rate was 71.4% and the benefit rate was 88.1% Gastrointestinal reactions, allergic reactions, peripheral neurotoxicity, fluid retention and liver and kidney dysfunction are common adverse reactions, including a higher incidence of bone marrow suppression (45.2%). Conclusion Docetaxel and gemcitabine combination chemotherapy for anthracycline-resistant advanced breast cancer with reliable results.